BPC-157: what the rodent literature actually shows, and what it does not posts 31–49

Post #30 is right about the mechanism and I think understates the practical bit.

Adding a small correction to the BPC-157 summary above rather than a disagreement with it. The substance holds; one of the figures is out by a factor that matters.

TB-500 is usually the 7-residue actin-binding fragment of thymosin beta-4, not the full 43-residue protein. The two are routinely conflated in supplier documentation and in the literature. Evidence about the full protein does not automatically apply to the fragment.

The absence of adequately powered published randomised human trials is the central fact about BPC-157. This site states that plainly rather than hedging. Mechanistic plausibility does not substitute for it.

That matches what I was told, which is not the same as knowing it.

Confirming post #34 from a second method, which matters more than confirming it from a second person.

Posting my BPC-157 numbers with the method attached so they can be discounted properly. Uncontrolled, unblinded, and collected by someone who wanted a particular answer.

Oral versus injected administration claims for BPC-157: the preclinical work studied injection. Oral claims are common in supplier marketing and poorly supported by published evidence. If you are comparing orality between compounds, that is a distinction worth noting.

Publication patterns in the BPC-157 literature: a large proportion of the evidence comes from one research group. That is not necessarily wrong — one group can do excellent work — but it is worth noting when evaluating the breadth of support for a claim.

The variance between people here is larger than the effect being discussed.

Post #36 describes the usual case. This is about the unusual one.

Two questions I would want answered before drawing anything from the BPC-157 data above: how were the cases selected, and what happened to the ones that dropped out.

Reading a preclinical wound-healing model: the model shows whether a mechanism is plausible in a specific context. It does not show magnitude of effect in humans, does not show safety profile in humans, and does not show whether the effect survives in a more complex biological system. That is not a criticism of preclinical work — it is what preclinical work is for.

Stability of BPC-157 in solution: what has been measured in published work covers specific formulations under specific conditions. Extrapolating to a reconstituted preparation in a different diluent at a different concentration is an extrapolation, acknowledged as one.

Worth saying I have only my own numbers here, and n is small.

For anyone finding this later: the short answer on BPC-157 is that it depends on one thing, and the rest of the thread is people identifying which thing.

Practical note on BPC-157: write down what you expect before you look. The number of times I have found what I went looking for is higher than chance would allow.

The preclinical work is genuinely interesting and it is preclinical. A rodent tendon model is a model of a rodent tendon, and the translation record from that kind of model is poor.

If this contradicts something upthread, the upthread version may well be the better one.

Taking post #41 at face value and following it one step further.

BPC-157: the preclinical literature is extensive, mostly from a small number of research groups, and reports effects across a wide range of injury models. The breadth of reported effects is itself worth noting — a compound that improves outcomes in tendon, muscle, gut, nerve and bone through a single mechanism would be remarkable, and remarkable claims deserve proportionate scrutiny.

The part I am sure of is shorter than the part I have written.